Mucocort AB has been granted a patent in China for its innovative products/technology. This patent was previously granted under the European Patent System (EPC).
The company, based at the Umeå Biotech Incubator, is developing an innovative mucoadhesive “patch” for canker sores (aphthous stomatitis), one of the most common oral mucosal diseases.
“We aim to become the world’s leading research and development company. This is a key element of our intellectual property portfolio and supports our commitment to ambitious intellectual property and market strategies. “This approval is a significant step forward in our global growth strategy,” said Jean. Mr. Lycke, Project Manager at Mucocort AB.
This product/technology has previously been approved under the European Patent System (EPC). Mucocort is currently actively working to extend its patent protection to more countries and further strengthen the global security of its products.
Professor Thomas Hedner, Member of the Board of Directors of Mucocort AB, added: “We are very proud that this patent has been granted in China, a country of great importance for both innovation and global growth. China is a strategically important market for us and this patent We can effectively protect our technology from infringement and strengthen opportunities to form partnerships and alliances within the region.”
